The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
(1976) · Medical Entomology and Zoology · Cited by 8,899
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationCompliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603 · cited 1×
“However, a number of epidemiological analyses have shown that non-adherence to second-generation antipsychotics is not much different than conventional compounds (Dolder et al., 2002; Gilmer et al., 2004; Valenstein et al., 2004).”
BackgroundLeucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Self-citationNeuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 435
Antipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents?
Dolder, C. R., Lacro, J. P., Dunn, L. B., & Jeste, D. V. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.103 · Cited by 386
Hogarty, G. E. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780120013001 · Cited by 365
Content and quality of 2000 controlled trials in schizophrenia over 50 years
Thornley, B., & Adams, C. (1998) · BMJ · doi:10.1136/bmj.317.7167.1181 · Cited by 364
Depot Antipsychotic Drugs: Place in Therapy
Davis, J. M., Metalon, L., Watanabe, M. D., & Blake, L. (1994) · Drugs · doi:10.2165/00003495-199447050-00004 · Cited by 295
Self-citationSystematic meta-review of depot antipsychotic drugs for people with schizophrenia
Adams, C. E., Fenton, M. K. P., Quraishi, S., & David, A. S. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.4.290 · Cited by 288
Important Issues in the Drug Treatment of Schizophrenia
Davis, J. M., Schaffer, C. B., Killian, G. A., Kinard, C., & Chan, C. (1980) · Schizophrenia Bulletin · doi:10.1093/schbul/6.1.70 · Cited by 284
Self-citationPoor Antipsychotic Adherence Among Patients With Schizophrenia: Medication and Patient Factors
Valenstein, M., Blow, F. C., Copeland, L. A., McCarthy, J. F., Zeber, J. E., Gillon, L., Bingham, C. R., & Stavenger, T. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007076 · Cited by 273
Chen, Y.-F. (2002) · Psychopathology · doi:10.1159/000065140 · Cited by 232
Falloon, I., Watt, D. C., & Shepherd, M. (1978) · Psychological Medicine · doi:10.1017/s0033291700006632 · Cited by 196
Depot perphenazine decanoate and enanthate for schizophrenia
David, A., Quraishi, S. N., & Rathbone, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001717.pub2 · Cited by 196
Neuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 195
Depot fluphenazine decanoate and enanthate for schizophrenia
David, A., Adams, C. E., Eisenbruch, M., Quraishi, S. N., & Rathbone, J. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000307 · Cited by 194
Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
da Silva Freire Coutinho, E., Fenton, M., & Quraishi, S. N. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001164 · Cited by 188
Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders
David, A., Adams, C. E., & Quraishi, S. N. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001470 · Cited by 180
Prevention of Relapse in Schizophrenia: An Evaluation of Fluphenazine Decanoate
Schooler, N. R. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140018002 · Cited by 177
Rifkin, A. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770130045004 · Cited by 175
Attitudes of Psychiatrists Toward Antipsychotic Depot Medication
Heres, S., Hamann, J., Kissling, W., & Leucht, S. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1216 · Cited by 152
Self-citationBarbui, C., Furukawa, T. A., & Cipriani, A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.070693 · Cited by 131
Gäebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., Eriksson, L., & Smeraldi, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.111 · Cited by 119
Antipsychotic long-acting injections: Prescribing practice in the UK
Barnes, T. R. E., Shingleton‐Smith, A., & Paton, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s37 · Cited by 114
The attitude of patients towards antipsychotic depot treatment
Heres, S., Schmitz, F. S., Leucht, S., & Pajonk, F. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3280c28424 · Cited by 99
Self-citationArango, C., Bombín, I., González-Salvador, T., García‐Cabeza, I., & Bobes, J. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.07.006 · Cited by 96
Ahn, J., McCombs, J. S., Jung, C., Croudace, T. J., McDonnell, D., Ascher‐Svanum, H., Edgell, E. T., & Shi, L. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00214.x · Cited by 84
Law, M., Morris, J. K., Jordan, R., & Wald, N. (2005) · Circulation · doi:10.1161/circulationaha.104.529628 · Cited by 78
Prevention of Recidivism of Schizophrenics Treated with Fluphenazine Enanthate
del Giudice, J., Clark, W. G., & Gocka, E. F. (1975) · Psychosomatics · doi:10.1016/s0033-3182(75)71232-x · Cited by 60
Prevention of Relapse in Schizophrenia
Geddes, J. R. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201033460112 · Cited by 58
Depot haloperidol decanoate for schizophrenia
Quraishi, S. N., David, A. S., Brasil, M. A. A., & Alheira, F. V. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001361 · Cited by 45
New Dimensions in the Pharmacologic Treatment of Schizophrenia and Related Psychoses
Buckley, P. F. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04314.x · Cited by 42
Identifying the profile of optimal candidates for antipsychotic depot therapy
Heres, S., Hamann, J., Mendel, R., Wickelmaier, F., Pajonk, F., Leucht, S., & Kissling, W. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.09.025 · Cited by 40
Self-citationBarnes, T. R. E., Milavić, G., Curson, D. A., & Platt, S. D. (1983) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00583530 · Cited by 38
Recent Advances in the Pharmacotherapy of Schizophrenia
Borison, R. L. (1997) · Harvard Review of Psychiatry · doi:10.3109/10673229709030552 · Cited by 36
Depot risperidone for schizophrenia
Hosalli, P., & Davis, J. M. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004161 · Cited by 33
Self-citationHamann, J., Mendel, R., Heres, S., Leucht, S., & Kissling, W. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.01.001 · Cited by 30
Self-citationDepot fluspirilene for schizophrenia
Abhijnhan, A., Adams, C. E., David, A. S., & Ozbilen, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001718.pub2 · Cited by 28
Depot pipotiazine palmitate and undecylenate for schizophrenia
Dinesh, M., David, A. S., & Quraishi, S. N. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001720.pub2 · Cited by 14
Depot bromperidol decanoate for schizophrenia
Adams, C. E., David, A. S., & Quraishi, S. N. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001719.pub2 · Cited by 8
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Self-citationMarder, S. R., & Cannon, T. D. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1808803 · Cited by 529
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395
Self-citation
Metadata
- Authors
- Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 127
- Issue
- 1-3
- Pages
- 83-92
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2013280864
- Cited by
- 419
- References
- 51
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.